He made it. Despite nausea and misery every week for eight weeks -- long after most other people would have dropped out of the clinical trial, according to the oncology nurse -- Mat finished the clinical trial drug cycle.
Unfortunately, AV-412 didn't quite match Mat's level of commitment. He had a CT scan on Tuesday, and got the results Wednesday. The cancer was technically stable over the eight weeks, but according to Dr. Ryan, there's stable-good, and stable-bad.
The results showed stable-bad. Although most of Mat's tumors (lungs, liver, and lymph nodes) stayed about the same size, there was noticeable growth in one in particular (a bone tumor) that led Dr. Ryan to think Mat should be in the market for a new drug. Dr. Ryan is looking into other clinical trial options, or Mat may revisit a drug he tried in 2006.
That was a combination of two drugs: adriamycin and streptozocin. Infusions every day for five days, and then a week off. That treatment was hard to tolerate, but not as hard as AV-412. We have AV-412 to thank for redefining our expectations.
And as I often say, it's all about expectations.